

July 15, 1968

Mr. Jerome Serchuck
Endo Laboratories
1000 Stewart
Garden City, New York 11533

Dear Mr. Serchuck:

I very much enjoyed our luncheon on Friday, and I want to thank you for the candor and the fine cooperation of Endo Laboratories which was expressed. We look forward to the opportunity to continue the assessment of naloxone, and hope that such studies will improve the present care provided these mentally ill.

The presentation and the attitudes expressed suggest, regrettably, that an adversary relationship, rather than one of cooperation, has developed. For my part, I must apologize for my demands, - demands that are expressed in a desire to maintain an experimental study program in man which requires continual justification and support by State and Federal authorities. We see the ready acquiescence of the community to a maintenance drug treatment model (as the enclosed report indicates), and regret that this is occurring without sufficient independent extensive testing.

The essence of my argument is that some of the problems in the evaluation of naloxone may be averted by more active consultations between industry and the clinicians. My suggestion is for an active collaborative relationship, so that the course of this complex program may be optimized. Such arrangements between industry and the academic community are not novel and may be useful here.

Again my thanks for a most pleasant luncheon and for the assurance of continued supplies of naloxone.

Sincerely yours,

Max Fink, M.D.
Director, Division of
Psychopharmacology

MF:kp

cc: Alfred M. Freedman, M.D.
Max Helfand, M.D.

enc. (2)

P.S. I am enclosing a recent review of the EEG studies of psychoactive drugs. Perhaps you may share this with Dr. Dunn and consider such studies formolindone. Perhaps he is already doing these in St. Louis or Princeton.